Scientific Presentations

International Conference on Antiviral Research (ICAR2024) (May 20-24, 2024 Gold Coast, Australia)

Travatrelvir, an Inhibitor of SARS-CoV-2 Main Protease now in Phase 1 Clinical Trials: in vitro Drug Resistance Compared to Nirmatrelvir 854.8 KB
Society for Investigative Dermatology (SID) Annual Meeting (May 15-18, 2024 Dallas, TX)

Rigosertib Demonstrates Considerable Efficacy and Safety in the Treatment of Advanced/Metastatic Cutaneous Squamous Cell Carcinoma in Patients with Recessive Dystrophic Epidermolysis Bullosa 440.4 KB
American Association of Immunologists (AAI) Annual Meeting (May 3-7, 2024 Chicago, IL)

Targeting the RAS/RAF/PI3K pathway for CD40 induction in melanoma cells to overcome resistance to anti-PD1 immunotherapies 1.9 MB
65th American Society for Hematology (ASH) Annual Meeting & Exposition (Dec 9-12, 2023 San Diego, CA)

Narazaciclib, a differentiated CDK4/6 antagonist, prolongs cell cycle arrest and metabolomic reprogramming, enabling restoration of ibrutinib sensitivity in BTKi-resistant mantle cell lymphoma 18.1 MB
San Antonio Breast Cancer Symposium (December 5-8, 2023 San Antonio, TX)

Narazaciclib’s differential targets and kinase inhibitory activity compared to the approved CDK4/6 inhibitors contribute to the enhanced inhibition of tumor growth in preclinical models 4.4 MB
European Academy of Dermatology and Venereology (EADV) 2023 Congress (October 11-14, 2023 – Berlin, Germany)

Efficacy and Safety of Rigosertib in Patients with Recessive Dystrophic Epidermolysis Bullosa 440.9 KB
International Conference on Malignant Lymphoma (June 13-17, 2023 - Lugano, Switzerland)

Prolonged cell cycle arrest by the CDK 4/6 antagonist narazaciclib restores ibrutinib response in preclinical models of BTKi-resistant mantle cell lymphoma 7.5 MB
American Society of Clinical Oncology Annual Meeting (June 2-6, 2023)

A pilot, open study to assess efficacy and safety of ON-01910 (rigosertib) in patients with recessive dystrophic epidermolysis bullosa associated locally advanced/metastatic squamous cell carcinoma 2.7 MB
ISID International Epidermolysis Bullosa Symposium/Osaka, JAPAN

Epidermolysis Bullosa Symposium presentation by Onconova Therapeutics May 9, 2023 4.1 MB
AACR Annual Meeting (April 14-19, 2023)

Synergistic activity of the CDK4/6 antagonist narazaciclib (ON 123300) with irreversible BTK inhibition in ibrutinib-resistant mantle cell lymphoma 36.4 MB

Differential targets engaged by narazaciclib in comparison to the approved CDK4/6 inhibitors contribute to enhanced inhibition of tumor cell growth 3.1 MB
AACR Special Conference: Targeting RAS (March 5-8, 2023)

CETSA profiling unveils novel targets engaged by anti-tumor drug rigosertib to inhibit RAS-MAPK signaling and trigger NLRP3 inflammasome activation 2.2 MB
European Society for Medical Oncology (Sept 9-13, 2022)

Phase 1/2 Trial of Rigosertib and Nivolumab for KRAS Mutated Non-Small Cell Lung Cancer (NSCLC) Patients 2.3 MB
American Society of Clinical Oncology Annual Meeting (June 3-7, 2022)

Narazaciclib’s kinase inhibitory activity is differentiated from approved CDK4/6 inhibitors in preclinical models 92.3 KB
Austrian Society of Dermatology and Venerology Annual Conference (Nov 25-27, 2021)

Rigosertib RDEB-SCC Poster Nov 2021 771.3 KB
3rd Annual RAS Targeted Drug Development Summit (Sep 21-23, 2021 digital event)

Phase I/2 Trial of Rigosertib & Nivolumab in KRAS-Mutated NSCLC in 2nd+ Line 1.6 MB
25th Congress of the European Hematology Association Digital Event (June 12-21, 2020)

EHA 2020 Audio Presentation EP829 - Dr. Koichi Takahashi MD 4.7 MB

MUTATIONS IN RAS PATHWAY GENES CORRELATE WITH TYPE OF FAILURE TO AZACITIDINE : GENOMIC ANALYSIS AT RANDOMIZATION ONTO THE INSPIRE TRIAL - SLIDE PRESENTATION - ABSTRACT EP829 955.6 KB

MUTATIONS IN RAS PATHWAY GENES CORRELATE WITH TYPE OF FAILURE TO AZACITIDINE: AT RANDOMIZATION ONTO THE INSPIRE TRIAL - SCIENTIFIC POSTER - ABSTRACT EP829 1.2 MB
61st American Society for Hematology Annual Meeting & Exposition in Orlando, FL (ASH 2019)

PHASE II STUDY OF ORAL RIGOSERTIB COMBINED WITH AZACITIDINE AS FIRST LINE THERAPY IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROMES (MDS) Abstract 566 1.2 MB

GENOMIC PROFILING IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME (HR MDS) FOLLOWING HMA FAILURE: BASELINE RESULTS FROM THE INSPIRE STUDY (04-30) Abstract 3015 550.4 KB

PHASE 2/3, MULTI-CENTER, INT’L, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF ORAL RIGOSERTIB + INJECTABLE AZACITIDINE (AZA) VERSUS INJECTABLE AZA IN TREATMENT-NAIVE PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME Abstract 4268 914.8 KB

THE INSPIRE STUDY IN HIGHER RISK MYELODYSPLASTIC SYNDROME (HR-MDS): A NOVEL PHASE 3 STUDY ADAPTIVE DESIGN FOR HEMATOLOGICAL MALIGNANCIES IN ADULTS Abstract 4249 415 KB

THE SEQUENCED COMBINATION OF RIGOSERTIB AND AZACITIDINE HAS MODULATORY EFFECTS ON CXCL8, RIG-I LIKE RECEPTOR AND Wnt/β-CATENIN SIGNALING AND DOWNSTREAM HEMATOPOIESIS PATHWAYS IN AN IN-VITRO MODEL OF THE MYELODYSPLASTIC SYNDROME Abstract #4231 638.7 KB
24th Congress of the European Hematology Association in Amsterdam (June 13-16, 2019)

PHASE II STUDY OF ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) Abstract S839 1.1 MB
15th International Symposium on Myelodysplastic Syndromes in Copenhagen (May 8-11, 2019)

PHASE II STUDY OF ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) Abstract: MDS19-0216 597.1 KB

RIGOSERTIB (RIG) MODULATES MAPK AND HEMATOPOIESIS SIGNALING AND SYNERGIZES AZACITIDINE (AZA) ALTERING VIRAL MIMICRY PATHWAY IN MYELODYSPLASTIC SYNDROME (MDS) Abstract: MDS19-0201 1.3 MB

EMERGENCE OF PTPN11 MUTATIONS IS ASSOCIATED WITH CLINICAL RESISTANCE TO RIGOSERTIB AND AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) Abstract: MDS19-0195 1.2 MB

UTILITY OF ADAPTIVE TRIAL DESIGN IN HIGHER-RISK MYELODYSPLASTIC (HR-MDS) SYNDROMES IN A PHASE 3 TRIAL OF INTRAVENOUS RIGOSERTIB: INSPIRE TRIAL Abstract: MDS19-0211 435 KB

EX VIVO RESPONSE PROFILING OF RIGOSERTIB IDENTIFIES DISTINCT CLASSES OF RESPONDERS IN MYELODYSPLASTIC SYNDROME Abstract: MDS19-0200 42.7 KB
Acute Leukemia Forum in Newport Beach, CA (April 11-12, 2019)

PHASE II STUDY OF ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS) 540.4 KB

ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) 247.3 KB

UTILITY OF ADAPTIVE TRIAL DESIGN IN A HIGHER-RISK MYELODYSPLASTIC (HR-MDS) SYNDROMES PHASE 3 TRIAL OF INTRAVENOUS RIGOSERTIB: INSPIRE TRIAL 443.3 KB
AACR Annual Meeting in Atlanta, GA (March 29-April 3, 2019)

RIGOSERTIB, A RAS-MIMETIC, INHIBITS MELANOMA CELL VIABILITY AND SYNERGIZES WITH ANTI-PD1 TO PROMOTE ANTI-TUMOR IMMUNE RESPONSE 13.5 MB
60th American Society of Hematology Annual Meeting (ASH 2018)

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients with Higher-Risk (HR) Myelodysplastic Syndromes: Efficacy and Safety Results in HMA Treatment Naive & Relapsed/Refractory Patients 1.1 MB

Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Rigosertib in a Phase I-II Study 336.6 KB

Evaluation of Underlying Cause of Genitourinary (GU) Adverse Events (AEs) in Patients with Myelodysplastic Syndromes upon Oral Administration of Rigosertib: Safety and Pharmacokinetic Analysis of Rigosertib across Three Clinical Trials 394.6 KB

Amelioration of Rigosertib Treatment Related Genitourinary Adverse Events in Patients with Myelodysplastic Syndromes: Implementation of Novel Dosing Regimen Derived through Pharmacokinetic Modeling in Phase 2 Study of Oral Rigosertib in Combination with A 343 KB
The 23rd Congress of the European Hematology Association in Stockholm

E-Poster: Emergence of PTPN11 Mutations is Associated with Clinical Resistance to the Combination of Azacitidine and Rigosertib in Patients with Higher-Risk Myelodysplastic Syndrome 1 MB
American Association for Cancer Research Annual Meeting 2018 (April 14-18, 2018)

Onconova Presents Data on Dual Inhibitor of CDK4/6 + ARK5 at American Association for Cancer Research 2018 Annual Meeting

Effect of Gender on the Rodent Pharmacokinetics of ON 123300, A Dual Inhibitor of ARK5 and CDK4-6, for the Treatment of Cancer 1 MB
6th International Bone Marrow Failure Disease Symposium (March 22-23, 2018)

Successful Risk-Mitigation Strategies to Reduce the Incidence of Hematuria in Patients (Pts) with Myelodysplastic Syndromes (MDS) Treated with Oral Rigosertib (RIGO) in Combination with Azacitidine (AZA) 373.4 KB
American Chemical Society National Meeting And Expo

Onconova Announces Two Presentations at 2018 American Chemical Society National Meeting and Expo
American Association for Cancer Research (AACR) Epigenetics Conference

Onconova Announces Presentation of Mechanism of Action Studies of Rigosertib Combination with Azacitidine 1 MB
American Society of Hematology Annual Meeting (ASH 2017)

Effects of Rigosertib (RIGO) Alone or in Combination with Azacitidine or Vorinostat on Epigenetic Reprogramming of CD34+ Cells in the Myelodysplastic Syndrome 1.1 MB

Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study 501.5 KB
American Association of Pharmaceutical Scientists Annual Meeting and Exposition

2017 AAPS Posters 305.7 KB
Key Opinion Leader Meeting on Pediatric RASopathies

Key Opinion Leader Meeting Presentation 25.1 MB
5th International RASopathies Symposium: Where Development and Cancer Intersect

July 28-30^th, 2017
Renaissance Orlando, FL

International RASopathies Symposium Presentation 13.8 MB
The 22nd Congress of the European Hematology Association in Madrid

EHA 2017 Presentation 1.5 MB

EHA 2017 Rigosertib Abstracts 326.2 KB

E-Poster: Rigosertib Combined with Azacitidine Epigenetically Modulates Chromatin and Hematopoietic Stem Cell Populations in MDS 520.1 KB

E-Poster: A Multicenter, Open-label, Phase 1 Clinical Study; Safety, Efficacy, and Pharmacokinetics of Oral Rigosertib in Japanese Patients with Recurrent/Relapsed or Refractory MDS 363.7 KB
2017 American Society of Clinical Oncology Annual Meeting

Relationship of Bone Marrow Blast (BMBL) response to Overall Survival (OS) in a Multicenter study of Rigosertib (Rigo) in Patien 296.7 KB
14th International Symposium on Myelodysplastic Syndromes

A Validation of a Post-Hypomethylating Agent Failure (HMAF) Prognostic Model in Myelodysplastic Syndromes (MDS) Patients Treated with Rigosertib versus Best Supportive Care (BSC) in a Randomized Controlled Phase III trial 424.9 KB

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS) 1.8 MB
American Association for Cancer Research Annual Meeting (AACR 2017)

ON 123300, an Orally Administered Novel CDK4/6 + ARK5 Inhibitor, Exhibits Potent Antitumor Activity In Vivo: Comparative Studies with Palbociclib 2.2 MB
American Society of Hematology Annual Meeting (ASH 2016)

Computational Analysis of Genomic Abnormalities from a Phase 3 Trial of Rigosertib in Higher-risk MDS - Simulation of a Predictive Signature for Clinical Response 316.6 KB

Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study 478.3 KB

Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) 267.3 KB
21st Congress of the European Hematology Association (EHA 2016)

Results from Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS) 2.1 MB
American Society of Clinical Oncology Annual Meeting (ASCO 2016)

INSPIRE: A randomized phase III trial of intravenous rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agents (HMAs) - Study design informed by subgroup analyses of ONTIME. 404.6 KB

Rigosertib (RIG) in combination with azacitidine (AZA) to modulate epigenetic effects and to overcome clinical resistance to hypomethylating agents (HMA) in myelodysplastic syndromes (MDS). 646.7 KB
American Association for Cancer Research Annual Meeting (AACR 2016)

Dual targeting of ARK5 and CDK4 pathways with ON123300 as a therapeutic strategy for colorectal carcinoma 2.3 MB
American Society of Hematology Annual Meeting (ASH 2015)

A Phase II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndromes (MDS) 659.2 KB
20th Congress of the European Hematology Association (EHA 2015)

Overall Survival (OS) and Baseline Disease Characteristics in MDS Patients with Primary HMA Failure in a Randomized, Controlled, Phase III Study of Rigosertib 1.4 MB

Correlation of Overall Survival (OS) with Bone Marrow Blast (BMBL) Response in Patients (Pts) with Myelodysplastic Syndromes (MDS) 1.4 MB

Prognostic and Predictive Value of IPSS-R in Assessing Overall Survival (OS) in a Phase III Study of Rigosertib in Second-line Higher-risk (HR) MDS Patients 1.4 MB

Subgroup Analyses of a Phase 3 Study in Patients with Myelodysplastic Syndromes Failing HMA Treatment: Identification of a Homogeneous Population Who Benefit from Rigosertib Therapy 404.1 KB
American Society of Clinical Oncology Annual Meeting (ASCO 2015)

Prognostic and Predictive Value of IPSS-R in Assessing Overall Survival (OS) in a Phase III Study of Rigosertib in Second-line Higher-risk (HR) MDS Patients 1.4 MB

Correlation of Overall Survival (OS) with Bone Marrow Blast (BMBL) Response in Patients (pts) with Myelodysplastic Syndrome 1.4 MB
13th International Symposium on Myelodysplastic Syndromes (MDS 2015)

Randomized Phase III Study of IV Rigosertib versus Best Supportive Care (BSC) in Patients with Higher-risk MDS (HR-MDS) After Failure of Hypomethylating Agents (HMAs) 1.6 MB

Mutational Profile and Karyotypic Abnormalities of a Cohort of Clinical Trial Patients with Higher-risk Myelodysplastic Syndromes (MDS) Following Failure of Hypomethylating Agents (HMAs): Impact on Response to Rigosertib Therapy 515.7 KB

Bone Marrow Blast (BMBL) Response Correlates with Overall Survival in Rigosertib-treated Patients with Higher-risk Myelodysplastic Syndrome After Failure of Hypomethylating Agents (HMAs): A New Response Criterion? 1.5 MB

A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine (AZA) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) 1.6 MB

Rigosertib, a Novel Inhibitor of Ras Signaling, Overcomes Azacitidine Resistance in Acute Myeloid Leukemia Cell Lines 17.4 MB
American Association for Cancer Research Annual Meeting (AACR 2015)

An In Vitro Platform to Dissect Drug Responsiveness in Refractory Anemia with Ringed Sideroblasts (RARS) 882.6 KB

Briciclib and its oral derivative (ON 013100) exhibit comparable anticancer activity in various preclinical cancer models 1.5 MB

The dual CK2/TNIK inhibitor, ON 108600, targets cancer stem cells and induces apoptosis of paclitaxel resistant triple-negative breast cancer cells 1.9 MB

Development of lipid-based nanosuspension formulation of first-in-class PLK2 inhibitor GBO-006 to treat triple negative breast cancer 809.9 KB
American Society of Hematology Annual Meeting (ASH 2014)

Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib vs Best Supportive Care in Patients with Higher-risk Myelodysplastic Syndrome After Failure of Hypomethylating Agents 720.5 KB

Mutational Profile and Karyotypic Abnormalities of a Cohort of Clinical Trial Patients With Higher-risk Myelodysplastic Syndromes (MDS) Following Failure of Hypomethylating Agents (HMAs): Impact on Response to Rigosertib Therapy 509.8 KB

Relationship of Bone Marrow Blast (BMBL) Response to Overall Survival (OS) in Patients with Higher-risk Myelodysplastic Syndrome (HR-MDS) Treated with Rigosertib After Failure of Hypomethylating Agents (HMAs) 1.9 MB

A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine (AZA) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML) 1.5 MB
American Society of Hematology Annual Meeting (ASH 2013)

Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses 911.1 KB

Predictors of Response to Rigosertib In Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents 397.9 KB
International Congress of Targeted Anticancer Therapies (TAT 2013)

Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemo-radiation treatment of cervical carcinoma, in vitro and in vivo. (Oral Presentation) Abstract #L08.04
American Society of Clinical Oncology Annual Meeting (ASCO 2012)

Phase I Study of Oral Rigosertib in Patients with Advanced Solid Tumors. 781.4 KB

A Phase 1 Study to Assess Oral Bioavailability of a Novel Oral Soft Gelatin Capsule Formulation of Rigosertib (ON 01910.Na) under Fasted and Fed Conditions in Patients with Myelodysplastic Syndromes. 1 MB
American Association for Cancer Research Annual Meeting (AACR 2012)

Nano-scale phospho-proteomic analysis to define diagnostic signatures and biomarkers of therapeutic activity in cancer. Abstract #1280

CXCL12 (SDF-1) and its Truncation Products in Patients with Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Receiving ON 01910.Na (Rigosertib) in Phase I Trials. 304.4 KB

Hyperphosphorylation and Desumoylation of RanGAP1-SUMO1. 523.7 KB
12th International Symposium on Myelodysplastic Syndromes (2013)

Rigosertib Activity in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents. 1.5 MB
American Society of Hematology Annual Meeting (ASH 2012)

Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies. 403.5 KB

Phase1/2 Single Arm Study of Rigosertib (ON 01910.Na) In Patients (Pts) with Relapsed or Refractory Acute Leukemia or Transformed Myeloproliferative Neoplasms. 191.8 KB

Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study. 371.4 KB
American Society of Hematology Annual Meeting (ASH 2011)

Oral Formulation of Rigosertib (ON 01910.Na) in Patient with Myelodysplastic Syndrome (MDS) - Phase I Study Results. 1.1 MB

Final Phase I/II Results of Rigosertib (ON 01910.NA) Hematological Effects in Patients with Myelodysplastic Syndrome and Correlation with Overall Survival. 2 MB

A Novel Nano-immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+ Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor ON 01910.Na (Rigosertib). 221.5 KB
American Chemical Society (ACS 2012)

Novel Cyano Pyridopyrimidines as Potent and Selective Inhibitors of CDK4 and Ark5 Kinases. 582 KB

Discovery of 6-Arylsulfonyl Pyridopyrimidinones as Potent and Selective PLK2 Inhibitors. 639.2 KB

Synthesis and Biological Evaluation of Z-Isomer of Rigosertib (ON 01910.Na) - a Clinical Stage (Phase III) Multi Kinase Anticancer Agent. 788.1 KB

Design, Synthesis and Biological Study of Novel Epidermal Growth Factor Receptor Kinase (EGFRK) Inhibitors. 1.5 MB
American Association for Cancer Research Annual Meeting (AACR 2013)
Radiation Research Society Annual Meeting (RRS 2012)

Human Safety Testing of Subcutaneously-Administered Ex-RAD® (ON 01210.Na), a Small Molecule Radioprotection Agent. 626.9 KB

Safety, Tolerability and Pharmacokinetic Behavior of Escalating Single Oral Doses of Ex-RAD® (ON 01210.Na) in Healthy Volunteers. 475.9 KB
American Association for Cancer Research Annual Meeting (AACR 2011)

Single-Cell Network Profiling (SCNP) to Evaluate the Proteomic Profiles Associated with ON 01910.NaTreatment of MDS Patients. 873.9 KB

RanGAP1-SUMO1 hyperphosphorylation (RGSH) and mitotic arrest by ON 01910.Na, okadaic acid or tubulin agents. 845.4 KB
American Society of Clinical Oncology Annual Meeting (ASCO 2013)

Phase II study of orally administered rigosertib (ON 01910.Na) in transfusiondependent lower risk myelodysplastic syndrome (MDS) patients. 2.9 MB

Scientific Presentations

International Conference on Antiviral Research (ICAR2024) (May 20-24, 2024 Gold Coast, Australia)

Society for Investigative Dermatology (SID) Annual Meeting (May 15-18, 2024 Dallas, TX)

American Association of Immunologists (AAI) Annual Meeting (May 3-7, 2024 Chicago, IL)

65th American Society for Hematology (ASH) Annual Meeting & Exposition (Dec 9-12, 2023 San Diego, CA)

San Antonio Breast Cancer Symposium (December 5-8, 2023 San Antonio, TX)

European Academy of Dermatology and Venereology (EADV) 2023 Congress (October 11-14, 2023 – Berlin, Germany)

International Conference on Malignant Lymphoma (June 13-17, 2023 - Lugano, Switzerland)

American Society of Clinical Oncology Annual Meeting (June 2-6, 2023)

ISID International Epidermolysis Bullosa Symposium/Osaka, JAPAN

AACR Annual Meeting (April 14-19, 2023)

AACR Special Conference: Targeting RAS (March 5-8, 2023)

European Society for Medical Oncology (Sept 9-13, 2022)

American Society of Clinical Oncology Annual Meeting (June 3-7, 2022)

Austrian Society of Dermatology and Venerology Annual Conference (Nov 25-27, 2021)

3rd Annual RAS Targeted Drug Development Summit (Sep 21-23, 2021 digital event)

25th Congress of the European Hematology Association Digital Event (June 12-21, 2020)

61st American Society for Hematology Annual Meeting & Exposition in Orlando, FL (ASH 2019)

24th Congress of the European Hematology Association in Amsterdam (June 13-16, 2019)

15th International Symposium on Myelodysplastic Syndromes in Copenhagen (May 8-11, 2019)

Acute Leukemia Forum in Newport Beach, CA (April 11-12, 2019)

AACR Annual Meeting in Atlanta, GA (March 29-April 3, 2019)

60th American Society of Hematology Annual Meeting (ASH 2018)

The 23rd Congress of the European Hematology Association in Stockholm

American Association for Cancer Research Annual Meeting 2018 (April 14-18, 2018)

6th International Bone Marrow Failure Disease Symposium (March 22-23, 2018)

American Chemical Society National Meeting And Expo

American Association for Cancer Research (AACR) Epigenetics Conference

American Society of Hematology Annual Meeting (ASH 2017)

American Association of Pharmaceutical Scientists Annual Meeting and Exposition

Key Opinion Leader Meeting on Pediatric RASopathies

5th International RASopathies Symposium: Where Development and Cancer Intersect

The 22nd Congress of the European Hematology Association in Madrid

2017 American Society of Clinical Oncology Annual Meeting

14th International Symposium on Myelodysplastic Syndromes

American Association for Cancer Research Annual Meeting (AACR 2017)

American Society of Hematology Annual Meeting (ASH 2016)

21st Congress of the European Hematology Association (EHA 2016)

American Society of Clinical Oncology Annual Meeting (ASCO 2016)

American Association for Cancer Research Annual Meeting (AACR 2016)

American Society of Hematology Annual Meeting (ASH 2015)

20th Congress of the European Hematology Association (EHA 2015)

American Society of Clinical Oncology Annual Meeting (ASCO 2015)

13th International Symposium on Myelodysplastic Syndromes (MDS 2015)

American Association for Cancer Research Annual Meeting (AACR 2015)

American Society of Hematology Annual Meeting (ASH 2014)

American Society of Hematology Annual Meeting (ASH 2013)

International Congress of Targeted Anticancer Therapies (TAT 2013)

American Society of Clinical Oncology Annual Meeting (ASCO 2012)

American Association for Cancer Research Annual Meeting (AACR 2012)

12th International Symposium on Myelodysplastic Syndromes (2013)

American Society of Hematology Annual Meeting (ASH 2012)

American Society of Hematology Annual Meeting (ASH 2011)

American Chemical Society (ACS 2012)

American Association for Cancer Research Annual Meeting (AACR 2013)

Radiation Research Society Annual Meeting (RRS 2012)

American Association for Cancer Research Annual Meeting (AACR 2011)

American Society of Clinical Oncology Annual Meeting (ASCO 2013)

Onconova Therapeutics

GET IN TOUCH

ABOUT ONCONOVA